Navigation Links
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
Date:4/9/2008

he populations with the highest rates of TB disease. TB is changing and evolving, making new vaccines more crucial to controlling the pandemic. Tuberculosis is now the leading cause of death for people living with HIV/AIDS, particularly in Africa. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are hampering treatment and control efforts.

About AdVac(R) technology and Ad35

AdVac(R) technology is a vaccine technology developed by Crucell and is considered to play an important role in the fight against emerging and re-emerging infectious diseases, and in biodefense. The technology supports the practice of inserting genetic material from the disease-causing virus or parasite into a "vehicle" called a vector, which then delivers the immunogenic material directly to the immune system. Most vectors are based on an adenovirus, such as the virus that causes the common cold. The AdVac(R) technology is specifically designed to manage the problem of pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5 (Ad5), without compromising large-scale production capabilities or the immunogenic properties of Ad5. AdVac(R) technology is based on adenoviruses that do not regularly occur in the human population, such as Ad35. In contrast to, for instance, Ad35 antibodies, antibodies to Ad5 are widespread among people of all ages and are known to lower the immune response to Ad5-based vaccines, thereby impairing the efficacy of these vaccines. All vaccine candidates based on AdVac(R) are produced using Crucell's PER.C6(R) production technology.

About PER.C6(R) technology

Crucell's PER.C6(R) technology is a cell line developed for the large-scale manufacture of biopharmaceutical products including vaccines. The production scale potential of the PER.C6(R) cell line has been demonstrated in an unprecedented successful bioreactor run of 20,000 liters. Compared to conventional pro
'/>"/>

SOURCE Aeras Global TB Vaccine Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
2. Artists for a New South Africa Will be Shaking The Blues at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb Mo, Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
9. Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School
10. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
11. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... FOREST, Ill. , March 6, 2015   Hospira, ... the U.S. Food and Drug Administration (FDA) on today,s FDA ... States . This is a watershed moment for improving ... As a leading global provider of biosimilars, Hospira has seen ... we are a proud participant in these early stages of ...
(Date:3/6/2015)... -- Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted ... announced that James A. Joyce , Aethlon Medical ... at the 27th Annual ROTH Conference on March 10, ... scheduled to present at 5:30 pm Pacific on March ... The Ritz-Carlton Hotel in Laguna Niguel, California ...
(Date:3/6/2015)... , March 6, 2015 Troyen A. ... Officer of CVS Health (NYSE: CVS ), ... in Washington, D.C. today.  Brennan ... role in addressing health care cost and quality as ... making CVS/pharmacy the first national pharmacy chain to stop ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3
... , March 23 The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim ( Germany ) ... ... ... ...
... medical device companies, today announced it has been selected by the Advanced Medical Technology Association (AdvaMed), as a member of the organization,s Business Solutions Program. , ... , ... ... ...
Cached Medicine Technology:Novalung Records 50% Growth 2Novalung Records 50% Growth 3AdvaMed Selects Prolifiq as Member of Business Solutions Program 2AdvaMed Selects Prolifiq as Member of Business Solutions Program 3AdvaMed Selects Prolifiq as Member of Business Solutions Program 4
(Date:3/6/2015)... Pokemini ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Mallory Sofastaii, a ... review and shared with viewers how this is a fully ... years, mobile games have benefited from building in a social ... users to connect their games to Facebook, see what level ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Saving Moses, ... around the world is traveling to Angola, Africa March ... of their malnutrition program. , This will be the ... in Angola, demonstrating their commitment to the region’s population ... The team will engage with the mothers and babies ...
(Date:3/6/2015)... Ticket Down is a reputable source for authentic ... Center. After being away from the touring business for ... of letting up on his “Garth Brooks World Tour.” The ... Yearwood, to venues around the United States. The duo recently ... to the Moda Center in Portland, OR. The husband and ...
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... 2015 As the Muscular Dystrophy Association ... the organization has hired two new Scientific Program Officers, ... will report to Grace Pavlath, Ph.D, who joined MDA ... Program Director, and together will lead MDA as it ... cures for various types of neuromuscular and motor neuron ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4
... ... offers a safe, gentle blend of natural active ingredients that provides temporary relief from common ... ... is in the air. This means itchy eyes, runny nose and sneeze-fests for millions of ...
... ... label. , ... (PRWEB) March 29, 2010 -- Advercan ( www.ADVERCAN.com ), 3M, and its sourcing ally, ... in 2007, and other interested media and beverage companies around Atlanta with very positive ...
... has positive effects, researchers say , MONDAY, March 29 (HealthDay ... people, Swedish researchers have found. , The study included 18 ... to cancer. They were offered a 25-minute hand or foot ... whether to have their massages at home, work or in ...
... ... are to offer Allergan implants as part of their standard breast augmentation package. ... (PRWEB) March 29, 2010 -- ... their ongoing attempt to provide the most comprehensive service to their patients having breast ...
... Payne Bolton School of Nursing at Case Western Reserve University ... cardiac rehabilitation program following a heart attack, bypass surgery or ... their hearts healthy. Women across the age ... comparison to men. Although all groups had a decline between ...
... , This release is available in ... may someday contain less fat and fewer calories, thanks ... as Mukti Singh. She,s based at the ARS National ... In experiments at her Peoria laboratory, Singh is ...
Cached Medicine News:Health News:New Natural Allergy Relief Available 2Health News:New Natural Allergy Relief Available 3Health News:Billions of Cleaner Beverage Can Tops Used as Billboard Space 2Health News:Rubicon Medical To Offer Allergan Implants In Breast Enlargement Surgery 2Health News:Study from CWRU Nursing School finds a year after cardiac event only 37 percent still exercising 2
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Concentrate System is a point-of-care system designed ... (also referred to as Platelet Rich Plasma ... from a small sample of blood. The ... factors, which are found in the platelets. ...
... II Platelet Concentrate System is a point-of-care ... Platelet Concentrate (also referred to as Platelet ... Plasma (PPP) from a small sample of ... body's natural growth factors, which are found ...
... Autologous growth factors (AGF) ... blood, the AGF gel delivers ... growth factors and proteins in ... the information of new bone ...
Medicine Products: